Pazopanib for Soft Tissue Sarcoma: — What It Can and Cannot Do

Fatigue, high blood pressure, diarrhoea, nausea, loss of appetite, and a change in hair colour are the most frequently reported. Hair often lightens or turns grey during treatment and usually returns to its original colour afterwards. Fatigue is the side effect that most commonly affects daily life. Tell your team how your energy levels are so they can consider a dose adjustment if the fatigue is severe.

Pazopanib blocks the same pathways that help regulate blood vessel tone, which causes blood pressure to rise in a significant proportion of patients — sometimes within the first week of treatment. Uncontrolled high blood pressure carries its own health risks independently of cancer, and your team needs to know about it so they can treat it. Check your blood pressure at home if you have a cuff. Call your team the same day if you develop a persistent headache, blurred vision, or a reading that feels unusually high for you.

Pazopanib can raise liver enzyme levels, sometimes significantly. Your team will check liver function tests before you start treatment and at regular intervals throughout. Most elevations settle when the dose is reduced or the drug is paused for a short period. A severe rise means treatment needs to be stopped. Tell your team immediately if your eyes or skin look yellow, your urine turns dark, or you develop pain in the upper right side of your abdomen — these are signs of more significant liver involvement.

Yes, and this is one of the things patients are not always told clearly at the start. Pazopanib must be taken on an empty stomach — food significantly increases how much of the drug enters your bloodstream, which raises the risk of side effects. Take it at the same time each day. Grapefruit and grapefruit juice interact with the drug and should be avoided throughout your treatment. The patient information leaflet that comes with your medicine has the full instructions, and your pharmacist can go through them with you.

Your team will arrange a CT scan after several weeks of treatment to assess whether the tumour has grown, stayed the same, or shrunk. Staying the same counts as benefit with this drug — stability is the goal, not a visible response on the scan. If the tumour has clearly grown despite pazopanib, your team will discuss whether a dose change, a treatment break, or a different approach is appropriate.

If the tumour progresses through pazopanib, other treatments may be considered depending on your sarcoma subtype, your overall fitness, and which treatments you have already received. Some subtypes have specific agents available; others have fewer established options. Asking your oncologist early — before you reach that point — what the likely next steps would be is a practical and reasonable question. It does not change your prognosis to ask; it helps you plan.